Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy

FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocyte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2024-07, Vol.30 (7), p.1795-1796
1. Verfasser:	Healey, Natalie
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedicine Cancer immunotherapy Cancer Research Cervical cancer Immunotherapy Infectious Diseases Lung cancer Lymphocytes Melanoma Metabolic Diseases Molecular Medicine Neurosciences News Solid tumors Tumor-infiltrating lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1796
container_issue	7
container_start_page	1795
container_title	Nature medicine
container_volume	30
creator	Healey, Natalie
description	FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. Image credit: Denis Pobytov / DigitalVision Vectors / Getty
doi_str_mv	10.1038/d41591-024-00040-2
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3063461086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3063461086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-cba7b6a658d1f80ac1de47cd220f91077300349857bff75dc70b34f36e6e978f3</originalsourceid><addsrcrecordid>eNqFkUtP3TAQha0KxKv9A11UkdiwCYwfsZ1lhUpBQmIDEqwsx7HvDUqcYCdF99936IVWYlFWHsnfOXNGh5CvFE4pcH3WClrVtAQmSgAQULJP5IBWQpZUwf0OzqB0qetK7pPDnB8R4lDVe2Sfa02lZPSAPNwuw5iKLoaun5Odu7gq-s0wrUe3mX1hpymNv2xfrH2yfZuL6J8LHIuAoil51-VujIWz0Xl0GYYljvMLO20-k91g--y_vL5H5O7ix-35ZXl98_Pq_Pt16ZgWc-kaqxppZaVbGjRYR1svlGsZg1DjAYpjalHrSjUhqKp1ChouApde-lrpwI_IydYXkz4tPs9m6LLzfW-jH5dsOEguJAUtET1-hz6OS4qYDinNOaU1gw8opjBUrZBiW8qlMefkg5lSN9i0MRTMSz1mW4_BesyfegxD0bdX66UZfPtX8tYHAnwLZPyKK5_-7f6P7W86rppa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3082710797</pqid></control><display><type>article</type><title>Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy</title><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Healey, Natalie</creator><creatorcontrib>Healey, Natalie</creatorcontrib><description>FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. Image credit: Denis Pobytov / DigitalVision Vectors / Getty</description><identifier>ISSN: 1078-8956</identifier><identifier>ISSN: 1546-170X</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/d41591-024-00040-2</identifier><identifier>PMID: 38816621</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biomedicine ; Cancer immunotherapy ; Cancer Research ; Cervical cancer ; Immunotherapy ; Infectious Diseases ; Lung cancer ; Lymphocytes ; Melanoma ; Metabolic Diseases ; Molecular Medicine ; Neurosciences ; News ; Solid tumors ; Tumor-infiltrating lymphocytes ; Tumors</subject><ispartof>Nature medicine, 2024-07, Vol.30 (7), p.1795-1796</ispartof><rights>Springer Nature Limited 2024</rights><rights>Springer Nature Limited 2024.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38816621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Healey, Natalie</creatorcontrib><title>Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. Image credit: Denis Pobytov / DigitalVision Vectors / Getty</description><subject>Biomedicine</subject><subject>Cancer immunotherapy</subject><subject>Cancer Research</subject><subject>Cervical cancer</subject><subject>Immunotherapy</subject><subject>Infectious Diseases</subject><subject>Lung cancer</subject><subject>Lymphocytes</subject><subject>Melanoma</subject><subject>Metabolic Diseases</subject><subject>Molecular Medicine</subject><subject>Neurosciences</subject><subject>News</subject><subject>Solid tumors</subject><subject>Tumor-infiltrating lymphocytes</subject><subject>Tumors</subject><issn>1078-8956</issn><issn>1546-170X</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkUtP3TAQha0KxKv9A11UkdiwCYwfsZ1lhUpBQmIDEqwsx7HvDUqcYCdF99936IVWYlFWHsnfOXNGh5CvFE4pcH3WClrVtAQmSgAQULJP5IBWQpZUwf0OzqB0qetK7pPDnB8R4lDVe2Sfa02lZPSAPNwuw5iKLoaun5Odu7gq-s0wrUe3mX1hpymNv2xfrH2yfZuL6J8LHIuAoil51-VujIWz0Xl0GYYljvMLO20-k91g--y_vL5H5O7ix-35ZXl98_Pq_Pt16ZgWc-kaqxppZaVbGjRYR1svlGsZg1DjAYpjalHrSjUhqKp1ChouApde-lrpwI_IydYXkz4tPs9m6LLzfW-jH5dsOEguJAUtET1-hz6OS4qYDinNOaU1gw8opjBUrZBiW8qlMefkg5lSN9i0MRTMSz1mW4_BesyfegxD0bdX66UZfPtX8tYHAnwLZPyKK5_-7f6P7W86rppa</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Healey, Natalie</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20240701</creationdate><title>Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy</title><author>Healey, Natalie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-cba7b6a658d1f80ac1de47cd220f91077300349857bff75dc70b34f36e6e978f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomedicine</topic><topic>Cancer immunotherapy</topic><topic>Cancer Research</topic><topic>Cervical cancer</topic><topic>Immunotherapy</topic><topic>Infectious Diseases</topic><topic>Lung cancer</topic><topic>Lymphocytes</topic><topic>Melanoma</topic><topic>Metabolic Diseases</topic><topic>Molecular Medicine</topic><topic>Neurosciences</topic><topic>News</topic><topic>Solid tumors</topic><topic>Tumor-infiltrating lymphocytes</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Healey, Natalie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Healey, Natalie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>30</volume><issue>7</issue><spage>1795</spage><epage>1796</epage><pages>1795-1796</pages><issn>1078-8956</issn><issn>1546-170X</issn><eissn>1546-170X</eissn><abstract>FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. Image credit: Denis Pobytov / DigitalVision Vectors / Getty</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38816621</pmid><doi>10.1038/d41591-024-00040-2</doi><tpages>2</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 1078-8956
ispartof	Nature medicine, 2024-07, Vol.30 (7), p.1795-1796
issn	1078-8956 1546-170X 1546-170X
language	eng
recordid	cdi_proquest_miscellaneous_3063461086
source	Nature; Alma/SFX Local Collection
subjects	Biomedicine Cancer immunotherapy Cancer Research Cervical cancer Immunotherapy Infectious Diseases Lung cancer Lymphocytes Melanoma Metabolic Diseases Molecular Medicine Neurosciences News Solid tumors Tumor-infiltrating lymphocytes Tumors
title	Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A32%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20infiltrating%20lymphocyte%20approval%20heralds%20new%20era%20for%20precision%20cancer%20immunotherapy&rft.jtitle=Nature%20medicine&rft.au=Healey,%20Natalie&rft.date=2024-07-01&rft.volume=30&rft.issue=7&rft.spage=1795&rft.epage=1796&rft.pages=1795-1796&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/d41591-024-00040-2&rft_dat=%3Cproquest_cross%3E3063461086%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3082710797&rft_id=info:pmid/38816621&rfr_iscdi=true